Our further experiments demonstrated that silencing CYTL1 enabled to facilitate intracellular ROS accumulation and impair migrative capacity of gastric cancer cells, indicative of CYTL1 as a possible therapeutic target of gastric cancer. Here, CYTL1 is linked to gastric cancer.